Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Croatia,Bulgaria,South Africa,Slovakia,France,Czech Republic,Russian Federation,Poland,Mexico,Finland
nct
MAJ Il y a 5 ans
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder. Relapse will be assessed using the MADRS scale.Patients who demonstrate improvement in depressive symptoms at the end of the initial 12-week open-label treatment period with SR58611A are randomized to continue SR58611A or switch to placebo under double blind conditions for up to 52 weeks of additional treatment. The secondary objective is to evaluate the safety of SR58611A in patients with MDD.
Pays
Argentina
,
Bulgaria
,
Croatia
,
Czech Republic
,
Finland
,
France
,
Mexico
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Slovakia
,
South Africa
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1